Follow The Filings

APRE Aprea Therapeutics

Aprea Therapeutics earnings company data as of 4:48 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 11 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by APRE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All APRE insider trades
  • $61K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Oren Gilad CEO
    Buy
    $25K 28,100 shares at $0.8900 +8.1% to stake
    Traded Jan 30 Filed Feb 2
    ↗
  2. John P. Hamill CFO
    Buy
    $5,073 5,700 shares at $0.8900 +21% to stake
    Traded Jan 30 Filed Feb 2
    ↗
  3. Marc Duey Director
    Buy
    $25K 21,459 shares at $1.17 +9.1% to stake
    Traded Dec 10, 2025 Filed Dec 11, 2025
    ↗
  4. John P. Hamill CFO
    Buy
    $5,825 5,000 shares at $1.17 +22% to stake
    Traded Dec 10, 2025 Filed Dec 11, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 10 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 3.01 Filing Doc
8-K 5.07 Filing Doc
SCHEDULE 13G — Filing Doc
424B7 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
424B3 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
424B3 Filing Doc
8-K 2.02,8.01,9.01 Filing Doc
10-K Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,3.02,7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.